Del Vecchio et al., 2012 - Google Patents
Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomasDel Vecchio et al., 2012
- Document ID
- 9214471947932499883
- Author
- Del Vecchio C
- Li G
- Wong A
- Publication year
- Publication venue
- Expert review of vaccines
External Links
Snippet
Glioblastoma multiforme (GBM) is the most common and deadly of the human brain cancers. The EGF receptor is often amplified in GBM and provides a potential therapeutic target. However, targeting the normal receptor is complicated by its nearly ubiquitous and high …
- 102000001301 EGF receptors 0 title abstract description 61
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Del Vecchio et al. | Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas | |
| Swain et al. | Targeting HER2-positive breast cancer: advances and future directions | |
| Song et al. | Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo | |
| Jin et al. | CD70, a novel target of CAR T-cell therapy for gliomas | |
| Palaia et al. | Immunotherapy for ovarian cancer: recent advances and combination therapeutic approaches | |
| Qi et al. | Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment | |
| Roth et al. | Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies | |
| Liu et al. | EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC | |
| Tandon et al. | Emerging strategies for EphA2 receptor targeting for cancer therapeutics | |
| Jing et al. | BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer | |
| Ramakrishna et al. | Prospects and challenges for use of CAR T cell therapies in solid tumors | |
| CN108473957A (en) | The method of the effect of improving Chimeric antigen receptor expression cell and amplification | |
| Xu et al. | The role of adaptive immunity in the efficacy of targeted cancer therapies | |
| Whilding et al. | ErbB-targeted CAR T-cell immunotherapy of cancer | |
| CA2968352A1 (en) | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents | |
| Alaia et al. | Ipilimumab for the treatment of metastatic prostate cancer | |
| Passiglia et al. | Immune-checkpoint inhibitors combinations in metastatic NSCLC: new options on the horizon? | |
| Palladini et al. | HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response | |
| Mooradian et al. | Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics | |
| Li et al. | Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma | |
| Mayer et al. | Novel targeted agents and immunotherapy in breast cancer | |
| Carter et al. | Immuno-oncology agents for cancer therapy | |
| Wang et al. | Are ovarian cancer stem cells the target for innovative immunotherapy? | |
| Ning et al. | Recent progress in antibody-based therapeutics for triple-negative breast cancer | |
| Huang et al. | Checkpoint CD24 function on tumor and immunotherapy |